RNACHealthcare · BiotechnologyThe 8 Wall Street analysts covering Cartesian Therapeutics, Inc. hold a median 12-month price target of $39 — +376.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Cartesian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RNAC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +376.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | Wedbush | Reiterates | Outperform | $38 |
| 10 June 2026 | Wedbush | Reiterates | Outperform | — |
| 10 June 2026 | Wedbush | Reiterates | Outperform | $38 |
| 9 June 2026 | BTIG | Reiterates | Buy | — |
| 9 June 2026 | BTIG | Reiterates | Buy | $44 |
| 9 June 2026 | Needham | Reiterates | Buy | — |
| 9 June 2026 | Needham | Reiterates | Buy | $40 |
| 27 May 2026 | Wedbush | Reiterates | Outperform | — |
| 26 May 2026 | Needham | Maintains | Buy | — |
| 12 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 May 2026 | Wedbush | Reiterates | Outperform | — |
| 10 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 9 Mar 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 9 Mar 2026 | Needham | Reiterates | Buy | — |
| 9 Jan 2026 | Needham | Maintains | Buy | — |
| 19 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2025 | BTIG | Maintains | Buy | — |
| 9 July 2025 | Wedbush | Initiates | Outperform | — |
| 8 May 2025 | Needham | Maintains | Buy | — |
| 9 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNAC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Cartesian Therapeutics, Inc. returned −17.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 3% of US stocks
Cheaper than 95% of US stocks
Cheaper than 70% of US stocks
Higher than 1% of US stocks
Higher than 35% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
Higher than 96% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cartesian Therapeutics, Inc. has a market value of $247.5M and an enterprise value of $164.0M.
Revenue in the twelve months to 30 June 2026: $1.5M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$151.9M, a −10283.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$78.6M.
Trailing P/E: 2.0×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Cartesian Therapeutics, Inc. employs 75 people — $20K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cartesian Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cartesian Therapeutics announced the granting of employment inducement awards to three new employees. The company is a late clinical-stage biotechnology firm focused on cell therapy for autoimmune diseases.
Why it matters — This signals new hiring at Cartesian, which may be relevant for RNAC watchers tracking the company's personnel and operational developments.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a late clinical-stage biotechnology company focused on cell therapy for autoimmune diseases, announced that its management expects to participate in several investor conferences scheduled for September.
Why it matters — RNAC watchers may be interested as the company's management will be presenting at upcoming investor conferences, potentially providing updates on its pipeline.
Cartesian Therapeutics announced it granted inducement stock option awards to four new employees, covering an aggregate of 115,250 shares of its common stock, with effective grant dates of August 3, 2026 and August 6, 2026.
Why it matters — A Cartesian Therapeutics watcher would note that the company is adding new hires through equity-based inducement awards as it advances cell therapy for autoimmune diseases.
Cartesian Therapeutics reported its second quarter 2026 financial results and issued a business update. The Phase 3 AURORA trial of Descartes-08 in myasthenia gravis is continuing, with data expected in the first quarter of 2027 and a biologics license application filing planned for mid-2027.
Why it matters — For RNAC watchers, the anticipated AURORA trial data and planned BLA filing mark key upcoming milestones for the company's lead product candidate, Descartes-08.
The 8 Wall Street analysts covering Cartesian Therapeutics, Inc. have a median 12-month price target of $39, with estimates ranging from $16 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Cartesian Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cartesian Therapeutics, Inc. 24 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Cartesian Therapeutics, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +376.8% from the last close, and Ticker Nerd's factor model ranks Cartesian Therapeutics, Inc. 24 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cartesian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNAC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $44 over the next 12 months.
Cartesian Therapeutics, Inc. returned -17.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases.
The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Cartesian Therapeutics Announces New Employment Inducement Grants". Cartesian Therapeutics announced the granting of employment inducement awards to three new employees. The company is a late clinical-stage biotechnology firm focused on cell therapy for autoimmune diseases.
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s current pipeline centers on autologous CAR-T programs designed to modulate immune activity and address serious conditions such as generalized myasthenia gravis, systemic lupus erythematosus, and certain forms of myositis. Its lead candidate, Descartes-08, is being advanced across multiple autoimmune indications, while additional programs such as Descartes-15 and Descartes-33 expand the company’s research beyond its lead asset. Cartesian Therapeutics emphasizes engineered cell therapy and proprietary manufacturing capabilities to create targeted treatments that fit within the broader fields of immunology, cell therapy, and precision medicine. Headquartered in Frederick, Maryland, Cartesian Therapeutics plays a specialized role in the biotechnology market by focusing on advanced therapies for difficult-to-treat immune-mediated diseases.
CEO Dr. Carsten Brunn Ph.D. · 75 employees · United States · https://www.cartesiantherapeutics.com
